Market closedNon-fractional
Taysha Gene Therapies/TSHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Taysha Gene Therapies
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
Ticker
TSHA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Dallas, United States
Employees
52
Website
www.tayshagtx.com
TSHA Metrics
BasicAdvanced
$457M
Market cap
-
P/E ratio
-$0.75
EPS
0.39
Beta
-
Dividend rate
Price and volume
Market cap
$457M
Beta
0.39
Financial strength
Current ratio
3.38
Quick ratio
3.209
Long term debt to equity
109.586
Total debt to equity
109.586
Interest coverage (TTM)
-21.67%
Management effectiveness
Return on assets (TTM)
-38.86%
Return on equity (TTM)
-606.69%
Valuation
Price to revenue (TTM)
25.355
Price to book
7.9
Price to tangible book (TTM)
7.9
Price to free cash flow (TTM)
-4.708
Growth
Revenue change (TTM)
96.39%
Earnings per share change (TTM)
-71.91%
3-year earnings per share growth (CAGR)
-40.71%
What the Analysts think about TSHA
Analyst Ratings
Majority rating from 10 analysts.
TSHA Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.4M
-5.56%
Net income
-$24M
-150.31%
Profit margin
-705.88%
-153.27%
TSHA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.93
$0.92
-$0.10
-
Expected
-$0.31
-$0.17
-$0.11
-$0.11
-$0.17
Surprise
22.14%
438.51%
-936.36%
-8.59%
-
TSHA News
AllArticlesVideos
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·3 weeks ago
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewsWire·1 month ago
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Taysha Gene Therapies stock?
Taysha Gene Therapies (TSHA) has a market cap of $457M as of July 27, 2024.
What is the P/E ratio for Taysha Gene Therapies stock?
The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of July 27, 2024.
Does Taysha Gene Therapies stock pay dividends?
No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Taysha Gene Therapies dividend payment date?
Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Taysha Gene Therapies stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.